Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating in a report issued on Thursday, TheStreetRatingsTable reports.
A number of other equities analysts have also commented on the stock. BidaskClub lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 29th. ValuEngine lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, September 20th. Finally, Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average price target of $24.44.
Shares of Amphastar Pharmaceuticals stock traded down $0.71 during midday trading on Thursday, reaching $18.41. 600,700 shares of the company’s stock traded hands, compared to its average volume of 195,968. The company has a market cap of $918.08 million, a price-to-earnings ratio of 87.67 and a beta of 1.17. Amphastar Pharmaceuticals has a 52 week low of $16.92 and a 52 week high of $25.43. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.83 and a current ratio of 2.81. The company’s 50 day simple moving average is $19.87 and its 200 day simple moving average is $20.65.
In other Amphastar Pharmaceuticals news, CEO Jack Y. Zhang sold 300,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $20.82, for a total value of $6,246,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,147,316 shares of the company’s stock, valued at $44,707,119.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Yakob Liawatidewi sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $20.73, for a total transaction of $103,650.00. Following the completion of the transaction, the senior vice president now directly owns 47,188 shares of the company’s stock, valued at $978,207.24. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 354,479 shares of company stock valued at $7,415,153. Insiders own 30.80% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new position in shares of Amphastar Pharmaceuticals in the second quarter worth about $88,000. Bank of Montreal Can raised its stake in shares of Amphastar Pharmaceuticals by 130.7% during the second quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock worth $104,000 after buying an additional 2,789 shares during the last quarter. Magnus Financial Group LLC bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth approximately $204,000. JPMorgan Chase & Co. raised its stake in shares of Amphastar Pharmaceuticals by 15.4% during the second quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock worth $205,000 after buying an additional 1,314 shares during the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth approximately $208,000. 47.21% of the stock is owned by institutional investors.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Featured Story: Initial Public Offering (IPO)
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.